OR WAIT 15 SECS
Naperville, Ill.-based Surfacide has recently been selected as a finalist for the 2015 Chicago Innovation Awards. The awards celebrate the most innovative new products and services in the Chicago region across all organization sizes, sectors and industries. Winners for each of the Chicago Innovation Awards categories will be announced at a gala event on Oct. 27 at the Harris Theater in Chicago.
Surfacide’s patented Helios® Triple Emitter UV-C Disinfection System utilizes ultra-violet (UV-C) light energy, an evidence-based method of controlling and eradicating microorganisms including those that are multidrug-resistant and cause healthcare-associated infections (HAIs).
UV-C light has been demonstrated in peer reviewed forums to be effective in eradicating microorganisms. Outmoded single emitter delivery systems based on first generation technology are not sufficiently advanced enough to be effective and efficient. Surfacide has changed all of that. Instead of utilizing one “emitter” of UV-C energy, the Helios system incorporates three separate emitters that are used during a single disinfection cycle. This advancement allows a larger space to be treated at one time and eliminates the inherent problems of first generation technology-shadowed regions and distances to surfaces. Furthermore, the system includes a validation component using proprietary laser mapping technology and algorithm on a handheld tablet. This results in a more intense level of energy being delivered to every surface in less time. Following a yearlong study using the Helios system, Faxton St. Luke’s hospital in Utica, N.Y. recently reported a 41 percent reduction in C. diff infection rates and a $1.4 million cost avoidance from eliminating the costs associated with these infections.
“We are thrilled and honored to be selected as a finalist for this prestigious award. I’m very proud of every member of the team that was so instrumental in designing this advanced technology that will benefit so many people around the world by reducing infections during hospital visits,” says Gunner Lyslo, Surfacide founder and CEO. “Surfacide’s Helios technology is consistently out-performing first generation, single emitter systems at hospitals around the world. This recognition further endorses Surfacide as a next generation thought leader and design leader of UV-C disinfection systems.”
Now in its 14th year, the Chicago Innovation Awards brings together Chicago’s business and civic leaders to recognize the most innovative new products and services introduced in the market. This year’s program attracted 535 nominees, which has been narrowed down to the top 100 finalists. All finalists are selected by a panel of accomplished judges representing a balanced portfolio of Chicago-area companies.
Source: Surfacide, LLC